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Abstract  
Ethnopharmacological relevance: Cancer patients in all cultures are high consumers of 
herbal medicines (HMs) usually as part of a regime consisting of several complementary 
and alternative medicine (CAM) modalities, but the type of patient, the reasons for 
choosing HM-CAM regimes, and the benefits they perceive from taking them are poorly 
understood. There are also concerns that local information may be ignored due to language 
issues. This study investigates aspects of HM-CAM use in cancer patients using two 
different abstracting sources: Medline, which contains only peer-reviewed studies from 
SCI journals, and in order to explore whether further data may be available regionally, the 
Thai national databases of HM and CAM were searched as an example. 
Materials and Methods: the international and Thai language databases were searched 
separately to identify relevant studies, using key words chosen to include HM use in all 
traditions. Analysis of these was undertaken to identify socio-demographic and clinical 
factors, as well as sources of information, which may inform the decision to use HMs.  
Results: Medline yielded 5,638 records, with 49 papers fitting the criteria for review. The 
Thai databases yielded 155, with none relevant for review. Factors associated with HM-
CAM usage were: a younger age, higher education or economic status, multiple 
chemotherapy treatment, late stage of disease. The most common purposes for using HM-
CAM cited by patients were to improve physical symptoms, support emotional health, 
stimulate the immune system, improve quality of life, and relieve side-effects of 
conventional treatment.  
Conclusions: Several indicators were identified for cancer patients who are most likely to 
take HM-CAM. However, interpreting the clinical reasons why patients decide to use HM-
CAM is hampered by a lack of standard terminology and thematic coding, because 
patients’ own descriptions are too variable and overlapping for meaningful comparison. 
Nevertheless, fears that the results of local studies published regionally are being missed, 
at least in the case of Thailand, appeared to be unfounded. 
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Introduction  
Cancer patients in all parts of the world are high users of herbal medicines (HMs), which 
they choose for clinical reasons related to their cancer diagnosis (Poonthananiwatkul 2015) 
and which they usually take as part of a regime consisting of several complementary and 
alternative medicine (CAM) modalities (Alsanad et al 2014; McLay et al 2012). The 
contribution of HMs cannot easily be separated from those of other forms of CAM, 
although they are more likely to possess pharmacological effects and/or interact with 
conventional medicines. The specific reasons why patients take HM-CAM regimes have 
not been completely identified but include trying to actively treat cancer, reduce symptoms 
of the disease, ameliorate side effects associated with conventional treatments, prevent 
further recurrence or metastasis of the cancer, and to enhance general health in order to 
deal with the disease and its treatment (Poonthananiwatkul 2015; Alsanad et al 2014; Ernst 
2009). A recent study of cancer patients at a traditional medicine hospice in Thailand 
suggested that in general herbal medicines were perceived to provide more benefit than 
harm, and a preliminary assessment of the herbal regime, using changes in symptom 
burden after staying at the hospice, supported this (Poonthananiwatkul 2015). HMs can be 
registered as medicines in the European Union, but not in most other countries, and 
‘nutritional’ products are poorly regulated everywhere. HMs are often sold as ‘food’ or 
‘dietary’ supplements to circumvent the regulations; however, as they are taken for 
therapeutic purposes they are considered to be HMs for the purposes of this study. The 
first step to addressing the problem of uncontrolled use of HMs as self-medication is 
therefore to explore the reasons why patients feel the need to take them. Perceptions of the 
efficacy and safety of these medicines influence the products chosen, although patients are 
unlikely to consider the indirect consequences of taking these medicines, including their 
interaction with conventional medicines or other supplements (Goey et al 2014; Zeller et al 
2013). The issues posed by combining herbal medicines with conventional drugs have 
been well documented over the last decade (e.g. Alsanad et al 2014; McLay et al 2012; 
Williamson et al 2013) and patients in many countries are now being advised to avoid 
taking herbal medicines during conventional cancer treatment, although no published 
evidence is available to confirm this as a policy. The objective of this review is to 
summarize the socio-demographic and other factors that influence HM-CAM use in cancer 
patients, and their perceptions towards their benefit or harm. 
Materials and methods 
Search strategy 
Data collected in ethnobotanical research has well-documented weaknesses, as critically 
reviewed by Heinrich et al (2009), and one of these is that datasets compiled regionally in 
local languages may not be available internationally. In order to investigate whether any 
such ‘hidden studies’ were available, two separate reviews were carried out: the first, a 
search of Science Citation Indexed, peer-reviewed journals in Medline; the second, a 
search of the national databases in Thailand. The purpose of the Thai review was to act as 
an example to investigate whether extra information could be gained by casting the net 
more widely, despite the unreliability of non-peer-reviewed sources. The Thai databases 
were used as a test case because Thailand is a very high user of herbal medicines, they are 
comprehensive and we had access to the full dataset. The searches were restricted to 2003 
onwards to provide a contemporary context and also because as a preliminary search found 
very few relevant studies prior to this. Even peer-review cannot guarantee quality so as 
many details as possible about each study (method, sample size, other findings) are 
included in table 1 to add context.   
Information sources and searches 
The global database Medline and the Thai on-line databases [Thailand Library Integrated 
System (ThaiLIS), Library of National Research Council of Thailand, Health Systems 
Research Institute Library, Thai Theses Online, Institute of Thai Traditional Medicine, 
Journal of Thai Traditional and Alternative medicine] (Thai Government 2014) were 
searched to identify literature on the experiences, attitudes or perceptions of cancer 
patients who had taken herbal medicines, using the following terms or their Thai language 
versions:  
1) Complementary  
2) Alternative  
3) Medicine  
4) Herbs  
5) 1 or 2 or 3 or 4  
6) Cancer  
7) Attitude  
8) 5 and 6 and 7  
9) Limited to English  
10) Limited to 2003 and 2014 
The off-line Khampramong research database was also searched using the same terms, as 
an example of an institutional data resources. All English language studies published 
between 2003 and 2014 identifying the experiences/ attitudes/ perceptions/ intended 
purposes of cancer patients regarding HM were included. Review articles, operational (e.g. 
clinical guidelines) and health services (e.g. cancer screening) research, case reports, 
studies on CAM which did not include HM use or surveys of other parties (such as 
physicians and other healthcare providers), and laboratory and animal studies were 
excluded. Studies looking purely at prevalence, trends and costs of herbal medicines were 
also omitted, as were studies on herb-drug combinations or side effects.  
Data extraction 
Full papers were obtained for studies considered relevant (figs 1 and 2) and read through 
by BP. To ensure validity, they were checked by Dr Saud Alsanad (College of Medicine, 
Al-Imam Mohammad Bin Saud Islamic University, Riyadh, KSA). The following data 
were extracted from the selected papers: author, year of publication, country, method used, 
response rate (%), sample size or calculation reported, cancer type, factors related to use of 
herbal medicine, purposes and thematic concepts cited for use. Factors such as age, gender, 
education level, income, type of cancer, previous conventional treatment and HM use were 
recorded, and also sources of information, which may influence decisions to use these 
products. Perceptions of benefit or harm resulting from taking these products were 
evaluated, but it must be emphasised that these are the opinions of patients who voluntarily 
took part in the studies cited, and are reported without any corroboration by independent 
assessment, clinical examination or biochemical tests. This is an intrinsic but unavoidable 
weakness of such studies. 
5,638 records were found in the Medline database, but only 170 were judged relevant 
based on the title, i.e. they specifically examined herbal medicine use in cancer patients. 49 
papers were eventually included in the review, as shown in figure 1. The Thai database 
search initially found 155 records, and 14 studies of herbal medicine use in cancer patients 
were selected based on the title (Fig 2). Titles and abstracts were read through by author 
BP and validated by a Thai speaker, Dr Supaporn Bunsiriluck (Sirindhorn College of 
Public Health, Thailand). No Thai language studies were found which fulfilled the criteria 
for inclusion, so no further analysis was undertaken for these studies.  
Insert figures 1 and 2 here 
Figure 1: Flow chart of the study selection process from the Medline database 
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Figure 2: Flow chart of the study selection process from the Thai national databases 
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Purposes cited by cancer patients for taking herbal medicines as part of a CAM regime 
The main reasons given by cancer patients as to why they use HM-CAM are illustrated in 
fig 3; which in fact shows that this type of analysis is not particularly useful, as there is so 
much overlap in potential meaning in the reasons cited by the patients themselves. We 
used the terms cited in the studies to try to avoid misinterpretation, but these are highly 
subjective. Not all studies used the same parameters, terminologies and methodologies, 
and more than one purpose was frequently cited by patients who also often used multiple 
types of CAM. Although all the studies reviewed included HM as a category of CAM, 
most could not differentiate findings from each modality, so it is not possible to ascribe all 
the findings to HM use. A further complication is that the line between HM and dietary 
supplements is not clear, and can depend on non-clinical issues such as legal classification. 
 CAM and HM in particular are to alleviate physical symptoms associated with cancer, but 
this category could easily include ‘improving general health and the ability to fight the 
disease’, as well as ‘treating cancer’ and ‘improving quality of life’, although these reasons 
were also described specifically. Similarly, ‘supporting emotional or mental health’ could 
include ‘taking an active role in treatment’, ‘managing stress’ and ‘feeling in control’. 
‘Stimulating or boosting the immune system’ was also considered very important, and 
whereas few studies reported that using HM was intended to achieve a longer life-span, 
this is implicit in most other categories such as preventing recurrence and treating or 
curing cancer. Only one study one suggested that ‘dissatisfaction with conventional 
medicine’, but the fact that so many cancer patients use HM-CAM suggests that they do 
not think that conventional medicine has all the answers. Fig 3 therefore also illustrates the 
importance of using standardised terminology or the use of thematic coding, rather than 
relying on patients’ own descriptions verbatim for this kind of study. Despite this, almost 
all of the categories relate to the desire to be actively involved in treatment, and the 
impetus to use HM-CAM comes from patients, rather than practitioners.  
 
 
Figure 3 Illustration of purposes cited by cancer patients for using herbal medicines as part 
of a CAM regime 
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sf
ac
ti
o
n
; 
3
.2
%
 r
ep
o
rt
ed
 n
o
 
ch
an
g
e;
 4
.4
%
 a
d
v
er
se
 e
ff
ec
ts
. 
1
0
 
T
re
v
en
a 
an
d
 
R
ee
d
er
 (
2
0
0
5
) 
 
N
e
w
 
Z
ea
la
n
d
 
T
Q
 
6
8
 
6
8
9
 
N
o
t 
ca
n
ce
r 
p
at
ie
n
ts
 
N
o
t 
as
se
ss
ed
. 
 
N
o
t 
as
se
ss
ed
; 
st
u
d
y
 w
as
 i
n
 
a 
 r
an
d
o
m
 s
a
m
p
le
 o
f 
4
3
8
 
ad
u
lt
s.
 
6
8
%
 s
ai
d
 ‘
b
en
e
fi
ci
al
 w
it
h
 
co
n
v
e
n
ti
o
n
al
 t
re
at
m
e
n
t’
; 
2
8
%
  
sa
id
 ‘
eq
u
al
 o
r 
b
et
te
r 
fo
r 
ca
n
ce
r’
  
1
1
 
H
el
y
er
 e
t 
al
. 
(2
0
0
6
) 
C
an
ad
a
 
S
A
Q
 
8
9
 
3
6
 
B
re
as
t 
 
‘C
u
re
’ 
ca
n
ce
r,
 h
el
p
 t
h
e 
b
o
d
y
 t
o
 h
ea
l,
 
b
o
o
st
 t
h
e 
im
m
u
n
e 
sy
st
e
m
 a
n
d
 f
ee
l 
in
 
co
n
tr
o
l 
o
f 
tr
ea
tm
e
n
t.
 A
n
x
ie
ty
 a
n
d
 
d
ep
re
ss
io
n
 f
o
u
n
d
 t
o
 b
e 
re
d
u
ce
d
 
M
an
y
 f
ac
to
rs
: 
e.
g
. 
m
ar
ri
ed
, 
y
o
u
n
g
er
, 
A
si
an
 e
th
n
ic
it
y
, 
h
ig
h
er
 s
o
ci
o
ec
o
n
o
m
ic
 c
la
ss
. 
 
6
0
%
 h
ad
 t
ak
en
 ‘
su
p
p
le
m
e
n
ts
’,
 
8
8
%
 a
lo
n
g
 w
it
h
 c
o
n
v
en
ti
o
n
al
 
d
ru
g
s;
 1
2
%
 s
ai
d
 H
M
 a
n
d
 D
S
 
co
u
ld
 r
ep
la
ce
 t
h
e
m
. 
N
o
 
A
u
th
o
r 
(y
ea
r 
 p
u
b
li
sh
ed
) 
C
o
u
n
tr
y
 
M
et
h
o
d
*
 
R
es
p
o
n
se
 
R
at
e 
(%
) 
S
am
p
le
 
si
ze
  
C
an
ce
r 
ty
p
e 
C
li
n
ic
al
 p
u
rp
o
se
 f
o
r 
h
er
b
al
 m
ed
ic
in
e 
u
se
 
an
d
/o
r 
th
em
at
ic
 a
n
al
y
si
s 
fi
n
d
in
g
s 
F
ac
to
rs
 a
ss
o
ci
at
ed
 w
it
h
 h
er
b
al
 
m
ed
ic
in
e 
u
se
 w
h
er
e 
id
en
ti
fi
ed
 
O
th
er
 s
tu
d
y
 f
in
d
in
g
s,
 i
f 
st
at
ed
 
1
2
 
H
u
m
p
el
 a
n
d
 
Jo
n
es
 (
2
0
0
6
) 
A
u
st
ra
li
a
 
ID
I 
- 
1
9
 
M
ix
ed
  
B
o
o
st
 i
m
m
u
n
e 
sy
st
e
m
, 
p
re
v
en
t 
ca
n
ce
r 
re
cu
rr
en
ce
, 
an
d
 i
m
p
ro
v
e 
p
h
y
si
ca
l 
an
d
 e
m
o
ti
o
n
al
 h
ea
lt
h
. 
 
C
an
ce
r 
d
ia
g
n
o
si
s 
o
r 
en
d
 o
f 
co
n
v
e
n
ti
o
n
al
 t
re
at
m
e
n
t 
p
ro
m
p
te
d
 C
A
M
 u
se
. 
T
h
e 
m
aj
o
ri
ty
 h
ad
 d
is
c
u
ss
ed
 w
it
h
 
th
ei
r 
d
o
ct
o
rs
. 
1
3
 
L
e
n
g
ac
h
er
 e
t 
al
. 
(2
0
0
6
) 
U
S
A
 
 
R
A
Q
 
- 
1
0
5
 
B
re
as
t 
 
T
o
 r
ed
u
ce
 s
y
m
p
to
m
s;
 e
sp
ec
ia
ll
y
 
‘p
sy
ch
o
lo
g
ic
al
’ 
d
is
tr
es
s.
  
H
ig
h
er
 l
ev
el
 o
f 
ed
u
ca
ti
o
n
; 
d
is
sa
ti
sf
ac
ti
o
n
 w
it
h
 m
ed
ic
al
 
tr
ea
tm
e
n
t;
 C
T
 
D
S
 a
ls
o
 u
se
d
 f
re
q
u
en
tl
y
. 
 
1
4
 
M
o
la
ss
io
ti
s 
et
 
al
. 
(2
0
0
6
) 
8
 E
U
 
co
u
n
tr
ie
s 
S
A
Q
 
- 
1
1
1
 
 
L
u
n
g
  
   
H
M
 m
ai
n
ly
 u
se
d
 t
o
 i
m
p
ro
v
e 
p
h
y
si
ca
l 
ab
il
it
y
 t
o
 f
ig
h
t 
ca
n
ce
r.
 
Y
o
u
n
g
er
, 
h
ig
h
er
 e
d
u
ca
ti
o
n
, 
p
re
v
io
u
s 
co
m
b
in
at
io
n
 
tr
ea
tm
e
n
ts
 f
o
r 
th
ei
r 
ca
n
ce
r.
 
H
M
 u
se
d
 b
y
 4
6
.4
%
; 
m
o
st
 f
o
u
n
d
 
b
en
ef
it
. 
In
fo
rm
a
ti
o
n
 f
ro
m
 m
ed
ia
, 
fr
ie
n
d
s,
 f
a
m
il
y
, 
p
ra
ct
it
io
n
er
s.
  
1
5
 
W
il
li
a
m
s 
et
 a
l.
 
(2
0
0
6
) 
 
U
S
A
 
S
A
Q
  
- 
3
7
 
M
ix
ed
 
P
ai
n
 o
r 
n
au
se
a 
o
f 
C
T
. 
D
S
 c
it
ed
 m
o
re
 c
o
m
m
o
n
ly
 
th
an
 H
M
. 
C
o
n
v
en
ti
o
n
al
 d
ru
g
s 
al
so
 u
se
d
 f
o
r 
sa
m
e 
p
u
rp
o
se
s.
 
1
6
 
W
o
n
g
-K
im
 &
 
M
er
ig
h
i 
(2
0
0
7
) 
U
S
A
 
S
S
I 
- 
3
0
 
B
re
as
t 
 
P
ai
n
 m
an
a
g
e
m
e
n
t.
  
N
o
t 
as
se
ss
ed
. 
C
A
M
/H
M
 t
h
o
u
g
h
t 
v
ia
b
le
 f
o
r 
p
ai
n
 
b
u
t 
co
st
 p
re
v
en
te
d
 r
eg
u
la
r 
u
se
. 
1
7
 
C
h
e
n
 e
t 
al
. 
(2
0
0
8
) 
C
h
in
a
 
R
A
Q
 
- 
5
0
4
6
 
B
re
as
t 
T
o
 a
ll
ev
ia
te
 m
e
n
o
p
au
sa
l 
sy
m
p
to
m
s 
an
d
 s
id
e 
ef
fe
ct
s 
o
f 
C
T
 a
n
d
 t
a
m
o
x
if
e
n
 
C
h
in
e
se
 H
M
 l
in
k
ed
 t
o
 
y
o
u
n
g
er
 a
g
e 
an
d
  
se
v
er
e 
m
en
o
p
au
sa
l 
sy
m
p
to
m
s 
7
5
%
 u
se
d
 f
o
r 
‘b
o
o
st
in
g
 t
h
e 
im
m
u
n
e 
sy
st
e
m
’.
 6
6
.7
%
 
co
n
si
d
er
ed
 i
t 
ef
fe
c
ti
v
e.
 
1
8
 
G
u
ll
u
o
g
lu
 e
t 
al
. 
(2
0
0
8
).
  
T
u
rk
e
y
 
S
A
Q
 
- 
1
2
9
 
B
re
as
t 
T
o
 s
u
p
p
o
rt
 t
h
ei
r 
g
en
er
al
 h
ea
lt
h
 s
ta
tu
s.
 
P
re
v
io
u
s 
u
se
; 
y
o
u
n
g
er
 a
g
e,
 
b
ei
n
g
 m
ar
ri
ed
, 
R
T
. 
 
3
4
%
 u
se
d
 c
o
n
v
e
n
ti
o
n
al
 t
re
at
m
en
t 
an
d
 o
th
er
 C
A
M
 w
it
h
 H
M
. 
 
1
9
 
K
re
m
se
r 
et
 a
l.
 
(2
0
0
8
) 
A
u
st
ra
li
a
 
S
A
Q
 
- 
3
6
7
 
B
re
as
t 
 
Im
p
ro
v
in
g
 w
el
lb
ei
n
g
, 
b
o
o
st
in
g
 i
m
m
u
n
e 
sy
st
em
, 
as
si
st
 i
n
 t
re
at
in
g
 c
an
ce
r,
 e
d
u
ce
 
re
cu
rr
en
ce
. 
H
M
 a
ss
o
ci
at
ed
 w
it
h
 y
o
u
n
g
er
 
ag
e;
 i
n
cr
ea
se
 i
n
 a
ll
 C
A
M
 i
n
 
ad
v
an
ce
d
 s
ta
g
es
 o
f 
d
is
ea
se
. 
H
M
 u
se
d
 b
y
 1
8
.7
%
: 
‘v
it
am
in
s’
 
b
y
 5
4
.2
%
; 
d
ie
t 
b
y
 2
3
.7
%
, 
ju
ic
in
g
 
6
.2
%
, 
T
C
M
 5
%
. 
 
2
0
 
L
u
 e
t 
al
. 
(2
0
1
0
) 
T
ai
w
a
n
 
ID
I 
- 
7
 
M
ix
ed
 
‘C
u
re
’ 
d
is
ea
se
, 
b
o
o
st
 i
m
m
u
n
it
y
, 
im
p
ro
v
e 
o
v
er
al
l 
h
ea
lt
h
, 
p
ro
lo
n
g
 l
if
e,
 
an
d
 p
ea
ce
 o
f 
m
in
d
. 
T
h
em
e
s 
fo
u
n
d
: 
co
p
in
g
 w
it
h
 
p
sy
ch
o
lo
g
ic
al
 a
n
d
 p
h
y
si
ca
l 
d
is
tr
es
s,
 l
if
es
ty
le
 d
is
ru
p
ti
o
n
. 
 
C
A
M
 u
se
rs
 e
x
p
re
ss
ed
 p
ra
ct
ic
al
 
co
n
ce
rn
s 
a
n
d
 w
a
n
te
d
 o
n
co
lo
g
is
ts
 
to
 b
e 
m
o
re
 i
n
fo
rm
ed
 a
b
o
u
t 
C
A
M
. 
2
1
 
P
ia
m
ja
ri
y
a
k
u
l 
et
 
al
. 
(2
0
1
0
) 
T
h
ai
la
n
d
 
R
A
Q
 
- 
2
0
2
 
M
ix
ed
 
C
A
M
 u
se
d
: 
d
ie
t/
li
fe
-s
ty
le
; 
m
in
d
 a
n
d
 
b
o
d
y
 c
o
n
tr
o
l;
 H
M
 ‘
fo
r 
h
ai
r 
lo
ss
’ 
N
o
t 
as
se
ss
ed
. 
S
el
f-
ca
re
 w
it
h
 C
A
M
 a
d
ju
n
c
t 
m
a
y
 
h
el
p
 p
at
ie
n
ts
 d
ea
l 
w
it
h
 t
h
e 
si
d
e 
ef
fe
c
ts
 o
f 
C
T
 a
n
d
 R
T
 
2
2
 
O
h
 e
t 
al
. 
(2
0
1
0
) 
A
u
st
ra
li
a
 
 
S
A
Q
  
2
8
.8
 
1
,3
2
3
 
M
ix
ed
  
N
o
t 
as
se
ss
ed
. 
M
o
st
 (
8
3
%
) 
w
o
u
ld
 b
e 
h
ap
p
ie
r 
to
 a
cc
ep
t 
C
A
M
 i
f 
o
ff
er
ed
 b
y
 t
h
e 
h
o
sp
it
al
. 
6
5
%
 u
se
d
 a
t 
le
as
t 
o
n
e 
fo
rm
 o
f 
C
A
M
; 
<
 3
%
 e
x
p
er
ie
n
ce
d
 a
d
v
er
se
 
ef
fe
c
ts
 f
ro
m
 H
M
/a
n
y
 C
A
M
. 
 
2
3
 
T
en
g
 e
t 
al
. 
(2
0
1
0
) 
C
h
in
a
 
 
S
S
I 
- 
1
2
1
 
M
ix
ed
 
‘C
u
re
’ 
ca
n
ce
r,
 b
o
o
st
 i
m
m
u
n
e 
sy
st
e
m
, 
in
cr
ea
se
 q
u
al
it
y
 o
f 
li
fe
, 
re
li
e
v
e
 c
an
ce
r 
sy
m
p
to
m
s,
 a
n
d
 o
th
er
s.
  
E
x
p
en
se
s 
fo
r 
C
A
M
 p
ai
d
 f
o
r 
4
0
%
 o
f 
to
ta
l 
m
ed
ic
al
 c
o
st
, 
W
es
te
rn
 m
ed
ic
in
e 
o
n
ly
 2
0
%
. 
V
er
y
 h
ig
h
 p
re
v
al
en
ce
 r
at
e.
 M
o
st
 
d
es
cr
ib
ed
 p
ar
ti
cu
la
r 
b
en
ef
it
s 
a
n
d
 
w
il
l 
co
n
ti
n
u
e 
to
 u
se
. 
 
2
4
 
W
an
ch
ai
 e
t 
al
. 
(2
0
1
0
) 
U
S
A
 
S
S
I 
- 
9
 
B
re
as
t 
  
C
o
p
e 
w
it
h
 d
is
ea
se
 a
n
d
 t
re
at
m
e
n
t,
 
e
m
o
ti
o
n
al
 s
u
p
p
o
rt
. 
K
in
sh
ip
, 
so
ci
al
, 
ed
u
ca
ti
o
n
al
, 
ec
o
n
o
m
ic
al
, 
an
d
 b
el
ie
fs
. 
 
S
o
m
e 
d
es
cr
ib
ed
 C
A
M
 a
s 
‘i
n
st
ru
m
e
n
t 
o
f 
G
o
d
’.
 
N
o
 
A
u
th
o
r 
(y
ea
r 
 p
u
b
li
sh
ed
) 
C
o
u
n
tr
y
 
M
et
h
o
d
*
 
R
es
p
o
n
se
 
R
at
e 
(%
) 
S
am
p
le
 
si
ze
  
C
an
ce
r 
ty
p
e 
C
li
n
ic
al
 p
u
rp
o
se
 f
o
r 
h
er
b
al
 m
ed
ic
in
e 
u
se
 
an
d
/o
r 
th
em
at
ic
 a
n
al
y
si
s 
fi
n
d
in
g
s 
F
ac
to
rs
 a
ss
o
ci
at
ed
 w
it
h
 h
er
b
al
 
m
ed
ic
in
e 
u
se
 w
h
er
e 
id
en
ti
fi
ed
 
O
th
er
 s
tu
d
y
 f
in
d
in
g
s,
 i
f 
st
at
ed
 
2
5
 
W
o
n
g
 e
t 
al
. 
(2
0
1
0
a)
 
S
in
g
ap
o
r
e 
R
A
Q
 
- 
6
5
 
M
ix
ed
 
L
o
n
g
er
 l
if
e,
 b
et
te
r 
q
u
al
it
y
 o
f 
li
fe
, 
im
p
ro
v
ed
 i
m
m
u
n
it
y
. 
B
ei
n
g
 m
al
e,
 a
d
v
a
n
ce
d
 
d
is
ea
se
. 
1
4
 p
at
ie
n
ts
 r
ef
u
se
d
 W
es
te
rn
 
m
ed
ic
in
e,
 u
se
d
 o
n
ly
 T
C
M
. 
 
2
6
 
 
W
o
n
g
 e
t 
al
. 
(2
0
1
0
b
) 
C
h
in
a 
 
R
A
Q
 
9
7
.5
 
8
2
 
B
re
as
t 
 
Im
p
ro
v
e 
q
u
al
it
y
 o
f 
li
fe
 i
n
 s
ev
e
ra
l 
ar
ea
s.
 
T
h
is
 w
a
s 
a 
cl
in
ic
a
l 
st
u
d
y
 o
n
 
a 
p
ar
ti
cu
la
r 
co
m
b
in
at
io
n
. 
Im
p
ro
v
e
m
e
n
t 
in
 s
le
ep
, 
fa
ti
g
u
e,
 
ap
p
et
it
e 
an
d
 e
m
o
ti
o
n
al
 h
ea
lt
h
  
2
7
 
A
li
-S
h
ta
y
e
h
 e
t 
al
. 
(2
0
1
1
) 
P
al
es
ti
n
e
 
R
A
Q
 
- 
1
2
6
0
 
M
ix
ed
  
N
o
t 
as
se
ss
ed
. 
M
o
st
 >
4
0
 y
rs
, 
fe
m
a
le
, 
in
 
ru
ra
l 
ar
ea
s.
  
H
M
 u
se
d
 a
s 
re
co
m
m
e
n
d
ed
 b
y
 
fa
m
il
y
 m
e
m
b
er
s 
(4
3
.5
%
).
  
2
8
 
D
a
m
er
y
 e
t 
al
. 
(2
0
1
1
) 
U
K
 
S
A
Q
 
7
5
.7
 
1
4
9
8
 
M
ix
ed
 
N
o
t 
as
se
ss
ed
. 
F
ew
er
 t
h
a
n
 2
0
%
 <
 5
0
 y
rs
 
o
ld
, 
m
o
st
 (
~
 6
0
%
) 
H
M
 u
se
rs
 
b
et
w
ee
n
 5
0
 -
 6
9
 y
ea
rs
. 
O
n
ly
 1
9
.7
%
 o
f 
p
at
ie
n
ts
 r
ep
o
rt
ed
 
H
M
 u
se
; 
re
m
ai
n
d
er
 u
se
d
 o
th
er
 
ty
p
es
 o
f 
C
A
M
. 
2
9
 
L
iu
 e
t 
al
. 
(2
0
1
1
) 
C
h
in
a
 
S
S
I 
- 
9
 
M
ix
ed
  
T
h
em
e
s 
id
en
ti
fi
ed
: 
H
M
 b
en
e
fi
ts
 w
er
e 
m
ed
ic
al
, 
so
ci
al
 a
n
d
 p
sy
ch
o
lo
g
ic
al
 
N
o
t 
as
se
ss
ed
. 
T
C
M
 u
se
d
 i
n
 a
d
d
it
io
n
 t
o
 
co
n
v
e
n
ti
o
n
al
 m
ed
ic
in
e.
 
3
0
 
A
m
ic
h
ai
 e
t 
al
. 
(2
0
1
2
) 
C
an
ad
a
 
S
S
I 
- 
1
2
 
L
u
n
g
 
T
h
em
e
s 
id
en
ti
fi
ed
: 
‘m
ai
n
ta
in
in
g
 
co
n
tr
o
l’
 a
n
d
 ‘
v
al
u
in
g
 w
el
ln
es
s’
 a
s 
fo
rm
 o
f 
se
lf
-h
el
p
. 
‘L
ea
rn
in
g
 n
e
w
 C
A
M
 
m
et
h
o
d
s’
 a
s 
a 
p
o
si
ti
v
e 
st
ep
 
fo
r 
se
lf
-h
el
p
 
P
at
ie
n
ts
 b
el
ie
v
ed
 t
h
at
 u
si
n
g
 H
M
 
af
te
r 
b
ei
n
g
 d
ia
g
n
o
se
d
 h
el
p
ed
 w
it
h
 
p
ro
g
n
o
si
s.
 
3
1
 
A
rt
h
u
r 
et
 a
l.
 
(2
0
1
2
) 
U
S
A
 
S
S
I 
9
2
 
2
3
 
M
ix
ed
 
T
o
 c
o
p
e 
w
it
h
 d
is
ea
se
; 
im
p
ro
v
e
 
q
u
al
it
y
 o
f 
li
fe
. 
O
p
ti
m
is
m
 a
n
d
 a
 b
el
ie
f 
th
at
 
o
n
e 
h
as
 t
h
e 
ab
il
it
y
 t
o
 a
ct
 t
o
 
ac
h
ie
v
e 
a 
g
o
o
d
 o
u
tc
o
m
e.
 
C
A
M
 u
se
rs
 a
ct
iv
e 
in
 d
e
v
el
o
p
in
g
 
tr
ea
tm
e
n
t 
p
la
n
s,
 w
h
ic
h
 i
m
p
ro
v
ed
 
th
ei
r 
q
u
al
it
y
 o
f 
li
fe
. 
3
2
 
B
en
-A
ry
e 
et
 a
l.
 
(2
0
1
2
)  
Is
ra
el
 
S
A
Q
 
- 
2
7
5
 
B
re
as
t 
/ 
G
y
n
. 
 
C
o
p
e 
w
it
h
 C
T
 e
ff
ec
ts
 a
n
d
 d
is
ea
se
, 
p
ro
v
id
e 
em
o
ti
o
n
al
 s
u
p
p
o
rt
. 
Y
o
u
n
g
er
 a
g
e,
 J
e
w
is
h
 
re
li
g
io
n
, 
b
u
t 
le
ss
er
 d
eg
re
e 
o
f 
re
li
g
io
si
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Factors associated with herbal medicines use as part of a CAM regime 
In general, the results supported other studies investigating the frequency of general CAM 
use which have found that a younger age, higher level of education and income, ethnicity and 
being female, were linked to HM-CAM use, as detailed in table 1. As far as cancer patients 
are concerned, this diagnosis appears to act as an impetus to using HM-CAM, with the 
intention of improving general health to ‘fight disease’ as well as cope with side effects of 
conventional drug treatment, in a way not usually associated with other disease states.   
The more serious disease states were associated with CAM which included HM and dietary 
supplements (HM-CAM). Multiple chemotherapy treatment was related to higher HM-CAM 
usage and many patients started using CAM (of any type) only after being diagnosed with 
cancer. However, those who had used HM-CAM for other purposes were also more likely to 
be associated with its use in cancer. A greater use of HM-CAM was noted in cancer patients 
who were in a recurrent or metastatic stage (e.g. Cui et al., 2004) and the longer the time 
since the initial cancer diagnosis, the more likely patients were to use HMs (Salminen et al., 
2004). These reasons may be related to other factors such as ‘fearfulness about the future’ 
and ‘anxiety about possible recurrence’, which were also linked with a greater tendency to 
use HM-CAM (Correa-Velez et al., 2003, Bismark et al., 2014).  
 
Experiences reported by patients after taking herbal medicines  
The recorded incidence of herbal use varies widely, i.e. between 10.8% and 90.2%, but all the 
studies reviewed showed that at least 55% of patients believed they had had benefited, 
whereas few patients (8% to 18%) reported negative effects (Damery et al., 2011, Nazik et 
al., 2012, Molassiotis et al., 2006, Chen et al., 2008, Tuna et al., 2013, Bonacchi et al., 2014). 
Perceived beneficial experiences: Previous studies have reported positive effects after HM-
CAM use but results varied greatly. Between 22% and 90% of patients said they had 
experienced benefits, the most common being relief of pain, dyspepsia and fever, and 
improved appetite and patterns of sleep (Oh et al., 2010, Molassiotis et al., 2005, 
Puataweepong et al., 2012, Hyodo et al., 2005, Teng et al., 2010, Ladas et al., 2014, Trevena 
and Reeder, 2005). Other perceived benefits were a greater ability to cope with the illness and 
its treatment or specific effects in relieving pain and adverse effects of conventional medicine 
including chemotherapy (i.e. nausea), as well as alleviating severe depression or anxiety and 
improving emotional health, as shown in table 1.  
Perceived negative experiences reported by patients after taking HMs: Negative effects from 
HM-CAM reported by cancer patients ranged from 3% to 9.4% and included pain, dyspepsia, 
abdominal pain and fatigue (Oh et al., 2010, Molassiotis et al., 2005, Puataweepong et al., 
2012, Hyodo et al., 2005, Trevena and Reeder, 2005). As with perceived benefit, it is not 
possible to ascribe all of these to the HM-CAM treatment and some may be due to 
progression of the disease. 
Other findings of the review  
Concurrent use with conventional therapies: most studies found that over 50% of patients 
who used HM-CAM did so along with conventional medicines (e.g. Nazik et al., 2012, Gupta 
et al., 2005, Helyer et al., 2006), many to treat specifically the adverse effects of conventional 
treatment (e.g. Gupta et al., 2005, McLay JS et al., 2012).  
Informing medical practitioners of HM use: differences were noted between countries but the 
number of studies cited was insufficient to draw any conclusions. Most strikingly, two US 
and two UK studies reported that the majority of patients surveyed did not tell their doctor of 
their HM-CAM use, whereas in two Australian studies, the majority either informed or 
intended to inform their doctor. In Turkey, Italy, Israel and Germany (1 study each), most 
patients discussed their HM-CAM use with their GP, but in Thailand, most did not (1 study).  
Discussion  
Many studies have investigated the use of CAM generally in cancer patients, which is 
commonplace (e.g. Teng et al 2010), and in some cases this has included HM (including 
dietary supplements). HM is the main form of CAM which can interact with conventional 
drugs, so the implications of HM use are more serious (e.g. Alsanad et al 2014) and therefore 
formed the focus of this investigation. As most users of CAM use more than one modality, 
we have examined all studies which specified the HM as part of their regime. Although in 
traditional Chinese medicine (TCM) for example, combining conventional with herbal 
medicine in cancer treatment is endorsed by physicians and may be beneficial (e.g. Hu et al 
2015; Cui et al 2004), patients usually used HM-CAM on their own initiative and without 
informing their doctor, and many considered it was not necessary to do so.  
The most common reasons for taking HM-CAM found in this study were linked to the desire 
to improve physical and mental symptoms and quality of life, and to help deal with the 
disease and its unpleasant treatment. As CAM is not sanctioned officially by most medical 
authorities, and not usually covered by public insurance schemes, it requires independent 
research into self-care health options, for example by using the internet and media. This may 
be a reflection of the findings that younger patients and those of a higher educational and 
financial status were associated with a higher use of HM-CAM.  
This study also showed that most of the relevant information on HM-CAM is available in the 
mainstream, peer-reviewed literature. A comprehensive set of Thai databases compiled from 
local studies was used as an example for exploration; however, it provided no new 
information and did not even identify two Thai clinical studies published internationally 
(Piamjariyakul et al 2010; Puataweepong et al. 2012). This is understandable since authors 
prefer to publish in SCI journals, although the results cannot be extrapolated elsewhere until 
further studies have been done.  
Conclusions  
This review identified several indicators for cancer patients who are most likely to take HM-
CAM, using information taken from Medline. Fears that the results of local studies published 
regionally are being missed, at least in the case of Thailand, appeared to be unfounded. In 
addition to patient characteristics as described above, the use of HM-CAM was also 
associated with the type and stage of cancer and the side-effects of conventional treatment 
experienced. However, interpreting the specific clinical purposes why patients decide to use 
HM-CAM, and what they expected of and experienced from the treatments, is hampered by a 
lack of standard terminology and thematic coding. Patients’ own descriptions are too variable 
and overlapping for meaningful comparison, but even so, most the categories relate to a 
desire to be actively involved in treatment, to improve general health and aid recovery. The 
impetus to use HM-CAM comes mainly from patients, rather than practitioners, except in 
China where integration of TCM and conventional medicine for cancer treatment is more 
common.  
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